Meet WuXi Biologics during J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco, January 7-10, 2019
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies

WuXi Biologics Congratulates Tychan on Completing Human Safety Studies for the First-in-Class Zika Virus Antibody in Record Speed
WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai

WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

January 14 -18, 2019
WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity

Announcing WuXiBody™ - A New Bispecific Antibody Technology Platform
WuXi Biologics Wins SCRIP Award for “Best Company in an Emerging Market”

WuXi Biologics Selected as Forbes Asia’s  Best Under A Billion  2018